FDA Approved

The first and only approved treatment
for recurrent pericarditis

ArcalystHeroUpAngle-REVISED 3-20.png



ARCALYST® (rilonacept) is the first and only FDA-approved treatment indicated for the treatment of recurrent pericarditis and the reduction in risk of recurrence.

ARCALYST, an IL-1 soluble decoy receptor, targets the underlying mechanism that drives inflammation in recurrent pericarditis. It is indicated to be used in adults and children 12 years and older.

 

View Press Release

ARCALYST at a glance

The Risk of Recurrence
Up to
30%
of individuals with acute pericarditis will experience a recurrence totaling ~40,000 patients.2,3

Learn more about the prevalence of recurrent pericarditis, the underlying cause of recurrent inflammation, and why reducing the risk of recurrence matters for your patients.

Powerful Results
In the pivotal trial,
96%
reduction in the risk of pericarditis recurrence
(hazard ratio: 0.04; p<0.0001).1

The efficacy and safety of ARCALYST were evaluated in RHAPSODY, a Phase 3, double-blind, placebo-controlled, event-driven, randomized withdrawal study (N=61).

The primary efficacy endpoint was time to first adjudicated pericarditis recurrence in the randomized withdrawal period.

SELF-ADMINISTERED TREATMENT
1x
Once weekly, self-administered subcutaneous injection.1

Get familiar with the safety profile, dosing and administration, and treatment duration of ARCALYST.

Access and resources

 

Kiniksa OneConnect offers patients support for injection training, financial assistance, and treatment logistics.